Retour

NICOX (EPA:COX) Nicox Extraordinary General Meeting of July 11, 2022

Directive transparence : information réglementée

22/06/2022 18:00

22/06/2022 18:00

Nicox Extraordinary General Meeting of July 11, 2022

03/06/2022 10:00

Number of voting rights as of June 3, 2022

23/05/2022 08:00

Nicox (COX): Eye health portfolio targets large markets

04/05/2022 07:30

Nicox: 2022 Ordinary Shareholder Meeting

11/04/2022 07:30

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of...

21/01/2022 07:30

Nicox Provides Fourth Quarter 2021 Business and Financial Highlights

02/07/2021 07:30

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b...

25/06/2021 07:30

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA®...

27/04/2021 07:30

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene...

23/03/2021 07:30

Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment...

Voir tous les communiqués de NICOX